U.S. to bar Varian's purchase of Impac

Article

The Justice Department plans to file suit to block Varian's $135 million purchase of Impac Medical Systems on the grounds that it would reduce competition in the sale of radiation therapy software and equipment.The government said the merger would

The Justice Department plans to file suit to block Varian's $135 million purchase of Impac Medical Systems on the grounds that it would reduce competition in the sale of radiation therapy software and equipment.

The government said the merger would substantially reduce competition among vendors of linear accelerators and radiation oncology management systems software.

Varian manufactures integrated cancer therapy systems. Impac makes oncology management systems and also supplies image management applications, including registration, scheduling, billing, and accounts receivable functions. Varian officials viewed the acquisition of Impac as an important move into the healthcare information systems field (SCAN, 6/21/00).

Varian manufactured about 60% of the linear accelerators sold in the U.S. in 1999. The government claims the proposed purchase would force competitors to rely on Varian to supply the software to support their machines and any advances they might introduce, reducing market pressures for innovation and price reductions.

The company reported record fourth quarter (end Sept. 29) sales, profit, and earnings per share. Sales were up 14% at $185 million, compared with $167 million for the same period a year earlier. Varian had sales of $704 million for fiscal 2000, compared with $599 million a year earlier.

Varian is headquartered in Palo Alto, CA. Impac is a privately held company in Mountain View, CA.

Newsletter

Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.

Recent Videos
SNMMI: Emerging PET Insights on Neuroinflammation with Progressive Apraxia of Speech (PAOS) and Parkinson-Plus Syndrome
Improving Access to Nuclear Imaging: An Interview with SNMMI President Jean-Luc C. Urbain, MD, PhD
SNMMI: 18F-Piflufolastat PSMA PET/CT Offers High PPV for Local PCa Recurrence Regardless of PSA Level
SNMMI: NIH Researcher Discusses Potential of 18F-Fluciclovine for Multiple Myeloma Detection
SNMMI: What Tau PET Findings May Reveal About Modifiable Factors for Alzheimer’s Disease
Emerging Insights on the Use of FES PET for Women with Lobular Breast Cancer
Can Generative AI Reinvent Radiology Reporting?: An Interview with Samir Abboud, MD
Mammography Study Reveals Over Sixfold Higher Risk of Advanced Cancer Presentation with Symptom-Detected Cancers
Combining Advances in Computed Tomography Angiography with AI to Enhance Preventive Care
Study: MRI-Based AI Enhances Detection of Seminal Vesicle Invasion in Prostate Cancer
Related Content
© 2025 MJH Life Sciences

All rights reserved.